KMT9 drives epithelial-mesenchymal plasticity and invasion in prostate cancer

Epithelial-mesenchymal transition (EMT) is a dynamic and reversible cell-state transition program that triggers tumour cell plasticity contributing to increase tumour heterogeneity, invasiveness and metastasis. Despite advances in the field, pharmacological strategies to target tumour plasticity remain limited. Here, we identify the histone lysine methyltransferase KMT9 as a novel epigenetic regulator of epithelial-mesenchymal plasticity and invasion in prostate cancer (PCa). Prostate-specific deletion of Pten and Trp53 in mice resulted in the generation of a mesenchymal tumour cell population expressing nuclear KMT9. We demonstrate that nuclear KMT9 is required for EMT in PCa cells after Pten and Trp53 loss. Mechanistically, we found that KMT9 chromatin occupancy was increased in mesenchymal tumour cells, repressing the expression of key genes for epithelial identity including Epcam, Cdh1 and multiple cytokeratins. Chromatin immunoprecipitation sequencing (ChIP-seq) revealed enrichment of KMT9 at the promoter regions of these essential epithelial “gate-keeper” genes. Functionally, mesenchymal tumour cells displayed a highly invasive and disseminating phenotype in tumour spheroid invasion assays, which was dependent on nuclear KMT9. Importantly, pharmacological inhibition of KMT9 using the highly selective and potent inhibitor KMI169, not only targeted the generation of mesenchymal tumour cells but also and blocked their invasive capacity. Together, our findings uncover KMT9 as a novel EMT regulator and identify a pharmacological approach to specifically target tumour cell plasticity and invasiveness in PCa, paving the way for the future development of KMT9-targeting therapies in cancer.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-20
DOI
https://doi.org/10.21203/rs.3.rs-11649851/v1
Primary Topic
Cancer Cells and Metastasis
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

KMT9 drives epithelial-mesenchymal plasticity and invasion in prostate cancer

Jon Peñarando, Eric Metzger, Manfred Jung, Ling Peng et al.
Research Square
Cancer Cells and Metastasis
preprint

KMT9 drives epithelial-mesenchymal plasticity and invasion in prostate cancer

Jon Peñarando, Eric Metzger, Manfred Jung, Ling Peng, Manuela Sum, Dominica Willmann, Roland Schüle, Sheng Wang, Sylvia Urban, A Rieder, Daniel METZGER, Franziska Pfefferle, Christian Gratzke
preprint en

Abstract

Epithelial-mesenchymal transition (EMT) is a dynamic and reversible cell-state transition program that triggers tumour cell plasticity contributing to increase tumour heterogeneity, invasiveness and metastasis. Despite advances in the field, pharmacological strategies to target tumour plasticity remain limited. Here, we identify the histone lysine methyltransferase KMT9 as a novel epigenetic regulator of epithelial-mesenchymal plasticity and invasion in prostate cancer (PCa). Prostate-specific deletion of Pten and Trp53 in mice resulted in the generation of a mesenchymal tumour cell population expressing nuclear KMT9. We demonstrate that nuclear KMT9 is required for EMT in PCa cells after Pten and Trp53 loss. Mechanistically, we found that KMT9 chromatin occupancy was increased in mesenchymal tumour cells, repressing the expression of key genes for epithelial identity including Epcam, Cdh1 and multiple cytokeratins. Chromatin immunoprecipitation sequencing (ChIP-seq) revealed enrichment of KMT9 at the promoter regions of these essential epithelial “gate-keeper” genes. Functionally, mesenchymal tumour cells displayed a highly invasive and disseminating phenotype in tumour spheroid invasion assays, which was dependent on nuclear KMT9. Importantly, pharmacological inhibition of KMT9 using the highly selective and potent inhibitor KMI169, not only targeted the generation of mesenchymal tumour cells but also and blocked their invasive capacity. Together, our findings uncover KMT9 as a novel EMT regulator and identify a pharmacological approach to specifically target tumour cell plasticity and invasiveness in PCa, paving the way for the future development of KMT9-targeting therapies in cancer.

Research Square
University of Freiburg (DE), University Medical Center Freiburg (DE), Institut de génétique et de biologie moléculaire et cellulaire (FR), Deutsches Konsortium für Translationale Krebsforschung (DE)
Good health and well-being
Cancer Cells and Metastasis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon